(Q38656524)

5 September 2017

title

Talimogene laherparepvec in the treatment of melanoma (English)

1 reference

5 September 2017

8

Alan Melcher

1 reference

5 September 2017

3

Christy Ralph

1 reference

5 September 2017

Karen Scott

5

0 references

author name string

Elizabeth S Appleton

1

1 reference

5 September 2017

Samantha Turnbull

2

1 reference

5 September 2017

Emma West

4

1 reference

5 September 2017

Kevin Harrington

6

1 reference

5 September 2017

Hardev Pandha

7

1 reference

5 September 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Expert Opinion on Biological Therapy

5 September 2017

published in

1 reference

5 September 2017

volume

15

1 reference

5 September 2017

issue

10

1 reference

5 September 2017

page(s)

1517-1530

1 reference

Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part II. Screening, education, and future directions

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Global cancer statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

The immune response to tumors as a tool toward immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

History of oncolytic viruses: genesis to genetic engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

21 January 2018

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Herpes simplex virus turns off the TAP to evade host immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Herpes simplex virus oncolytic vaccine therapy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1084280

10.1517/14712598.2015.1084280

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference